英國IDS(Immunodiagnostic Systems Limited) www.idsplc.com
英國ＩＤＳ公司成立于1977年。主要擅長(zhǎng)于骨代謝系列酶免診斷試劑，其維生素Ｄ系列試劑盒曾于１９９９年榮獲女王技術(shù)成就獎(jiǎng)?，F(xiàn)已成為體外診斷試劑行業(yè)全球公認(rèn)的創(chuàng)新者和市場(chǎng)佼佼者。
? －特別在骨疾病和鈣吸收功能紊亂（骨質(zhì)疏松、骨軟化、變形性骨炎）輔助診斷和治療療效監(jiān)測(cè)　　　工具開發(fā)、實(shí)際應(yīng)用方面及上述骨異?；驹頇C(jī)制研究方面，英國IDS公司以經(jīng)驗(yàn)豐富而聞名于全球。
? －公司的旗艦產(chǎn)品：
? 　維他命D測(cè)定試劑盒（血清）：人體鈣儲(chǔ)量的控制和部署的一個(gè)重要標(biāo)記物
　鈣對(duì)于年輕人的骨骼和牙齒健康成長(zhǎng)，老年人的鈣保持及缺乏陽光照射的人非常重要。
　　維他命D不足與日益增多的癌癥（如乳腺癌、前列腺癌和結(jié)腸癌）也有緊密聯(lián)系
?－ 1999年榮獲技術(shù)成就女王獎(jiǎng) （由于公司在維他命D方面的貢獻(xiàn)及其在國際市場(chǎng)上取得的杰出成果）。
?－ IDS已在日本市場(chǎng)取代原來占主導(dǎo)地位的國內(nèi)競(jìng)爭(zhēng)對(duì)手，從而占據(jù)優(yōu)勢(shì)地位。
?－ IDS產(chǎn)品已在國際主流市場(chǎng)上獲得最大化的收入和利潤(rùn)。其在英國國內(nèi)的銷售額還不足整個(gè)全球診斷試劑市場(chǎng)的5%。
? －2003年在亞利桑那州成立美國IDS公司，其中美國市場(chǎng)占據(jù)全球銷售額的35-40%。 
? －2004年年底成立德國IDS公司，并于2005年2月1日全面運(yùn)營。
? －2004年成立IDS上市集團(tuán)，并在12月24日正式開始擁有AIM的參股貿(mào)易（代碼：IDH）。
? －2005年2月，成功收購芬蘭SBA公司。該公司的核心技術(shù)是測(cè)定破骨細(xì)胞活性的關(guān)鍵標(biāo)記物：TRACP 5b （血清或血漿），目前已有人、小鼠和大鼠酶免試劑盒。
? －2005年底正式授予北京榮志海達(dá)生物科技有限公司中國總代理。

英國IDS公司，酶免試劑專家！
骨代謝產(chǎn)品
?－ 抗酒石酸酸性磷酸酶5b （BoneTRAP5b）（EIA） （已獲專利）
?－ 骨特異性堿性磷酸酶（BAP）（EIA） 
? －25羥基維他命 D/ 1,25雙羥基維他命 D（EIA） （已獲專利）
? －全段甲狀旁腺激素（I-PTH）（EIA）
? －類胰島素生長(zhǎng)因子（IGF-1）（EIA）
? －可溶性破骨細(xì)胞異化因子（Srankl）

IDS is headquartered in the UK, and has subsidiaries in the USA, Germany, France, Denmark, Finland and Belgium, offering next day delivery in all major territories. The markets of Spain, Italy, Australia, Japan and elsewhere are serviced by a network of highly qualified and experienced distributors. You will find full contact details of all of these outlets on this website.

The company enjoys a dominant position in the provision of immunoassay kits for the determination of Vitamin D (for the more technical, both 25 Hydroxy- and 1,25 Dihydroxy- Vitamin D). We are determined to remain at the forefront of Vitamin D testing globally, and the appearance of fully automated Vitamin D on the IDS-iSYS underlines this determination.
Our track record of delivering innovative new products, by de novo or collaborative programmes with academia, or the judicious acquisition of complementary products and/or companies, has given IDS the broadest range of bone and skeletal biomarker kits available anywhere in the world.
Our entry into the automated analyser market heralds a new phase of growth for IDS. The IDS-iSYS is a push-button, walk away instrument that is multi-competent - a fully-automated immunoanalyser that can simultaneously run biochemistry and haemostasis tests from the same patient primary sample tube.

IDS meet the needs of its pharmaceutical and clinical customers by providing a range of Research Use Only kits for researchers in drug development and pre-clinical studies, and in offering fully-optimised and validated ?human? kits for ensuing clinical studies, and ultimately for use by the Clinical Chemist for routine IVD purposes.
With fully-automated instrumentation, IDS will compete more effectively for the larger accounts in reference laboratories and Clinical Research Organisations, whilst also easing the pressure of growing volumes of testing being experienced by small to mid sized laboratories.
The increase in the aging population throughout the world has resulted in a higher incidence of conditions such as osteoporosis, rheumatoid and osteo- arthritis, renal and cardiovascular disease. The spiralling socio-economic costs of fractures and other age-related morbidities are driving the need for better tools to monitor health and diagnose disease onset much earlier, and IDS intends to play a full part in this.
IDS is a listed company, traded on the Alternative Investment Market (AIM; trading symbol IDH) of the London Stock Exchange.